Live Breaking News & Updates on Presented June

Stay updated with breaking news from Presented june. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Debate: Initial Combination Therapy for Type 2 Diabetes?

Two diabetes research giants, Ralph DeFronzo, MD, and David Nathan, MD, faced off on whether to use initial combination therapy versus starting with metformin and adding more medications sequentially. ....

San Antonio , United States , University Of Texas , Ralpha Defronzo , Davidm Nathan , Diabetes Center At Massachusetts , Clinical Research Center , University Of Texas Health , Novo Nordisk , Boehringer Ingelheim , American Diabetes Association , Scientific Sessions , Addressing Multiple Underlying Defects , Texas Health , United Kingdom Prospective Diabetes Study , Medical Care , Far More Data , Lower Cost , Diabetes Center , Massachusetts General Hospital , Presented June , Diabetes Mellitus Type 2 , Iabetes Mellitus Type Ii , Type 2 Diabetes , Sglt2 Inhibitors , Odium Glucose Transporter 2 Inhibitors ,

33% of Type 1 Diabetes Patients Insulin-Free With Stem Cells

Engraftment of Vertex Pharmaceutical s VX-880 stem cell–derived islets has now been achieved in six patients, two of whom are insulin-independent at 1 year. ....

United States , Maria Cristina Nostro , Trevorw Reichman , Sernova Inc , Scientific Sessions Of The American Diabetes Association , Vertex Pharmaceuticals , University Of Toronto , Mcewen Stem Cell Institute , Islet Cell Transplantation , Scientific Sessions , American Diabetes Association , Medscape Medical News , Meet Primary Endpoint , Three More , Sigilon Therapeutics , Universal Cells , American Diabetes , Presented June , Diabetes Mellitus Type 1 , Iabetes Mellitus Type I , Type 1 Diabetes , Transplantation Stem Cell , Ransplantation Hematopoietic Stem Cell , Hematopoietic Stem Cell Transplantation , Stem Cell Transplantation , Stem Cell Therapy ,

Pegozafermin Improves Fibrosis in NASH in Phase 2b Study

In the phase 2b ENLIVEN trial, the investigational drug pegozafermin met both primary endpoints at 24 weeks and led to improvements in fibrosis, paving the way for phase 3 development. ....

United States , San Diego , University Of Chicago , Michael Charlton , Rohit Loomba , International Liver Congress , Division Of Gastroenterology , University Of California , University Of Chicago Medicine , European Association , New England Journal , Activity Score , Liver Diseases , Chicago Medicine , Liver Congress , Presented June ,

OASIS and PIONEER PLUS Support High-Dose Oral Semaglutide

Higher doses of oral semaglutide (25 mg and 50 mg) seem to be effective in type 2 diabetes and obesity, improving upon results obtained with currently approved maximum dose of oral semaglutide 14 mg daily. ....

Harvard University , United States , North Carolina , Andrewy Hwang , Christinah Sherrill , Filipk Knop , Vanitar Aroda , Marion Pragnell , American Diabetes Association , Novo Nordisk , University Of Copenhagen , Health Sciences University , High Point University , Scientific Sessions , Chair Marion Pragnell , Medscape Medical News , Daily Pill , Adults With Overweight , Inadequately Controlled Type , Presented June , Diabetes Mellitus Type 2 , Iabetes Mellitus Type Ii , Type 2 Diabetes , Weight Loss , Glp 1 Receptor Agonists , Glucagon Like Peptide 1 Receptor Agonists ,

CGM Alarm Fatigue in Youth?

Teenagers often set the alarms on their continuous glucose monitors to levels that cause needless distress, researchers found. ....

United States , Indiana University , Indiana University School Of Medicine , Endocrine Society , University Of Colorado , University Of Colorado Barbara Davis Center , Victoria Ochs , Indiana University School , Barbara Davis Center , Cari Berget , Medscape Medical , Presented June , Continuous Glucose Monitoring Cgm , Adolescent Medicine , Insulin Pump , Continuous Subcutaneous Insulin Infusion , New York , Diabetes Mellitus Type 1 , Iabetes Mellitus Type I , Type 1 Diabetes ,